{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:21:12Z","timestamp":1777922472495,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Palliat Care"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Motor neuron disease (MND) is a progressive neurological disorder with no known cure that damages motor neurons. The purpose of this analysis is to examine the place of death for MND patients in the United States during the coronavirus disease 2019 (COVID-19) pandemic and to investigate the extent of specific comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We obtained death certificate and associated comorbidities data for all U.S. MND deaths from 2018 to 2021 and conducted a population-based cross-sectional analysis of the deaths pre-COVID-19 (2018-2019) and during COVID-19 (2020-2021). We hypothesized that place of death and comorbidities associated with place of death for MND patients in the United States were altered during the COVID-19 pandemic in comparison to the 2 years period before the pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed 30\u2005066 MND deaths (14\u2005562 pre-COVID-19 and 15\u2005504 during COVID-19) aged 20 years and older. During COVID-19, MND deaths at home increased (54.4% vs 45.5% pre-COVID). Hispanic individuals had an increased likelihood of dying at home compared to a nursing home or hospice (OR\u2009=\u20091.57, 95%CI: 1.22-2.02), but a decreased likelihood compared to a hospital (OR\u2009=\u20090.61, 95% CI: 0.51-0.72). Among the top comorbidities listed, there was a 27.8% increase in diabetes mellitus and a 20.2% increase in essential hypertension during COVID-19. During COVID-19, diabetes mellitus was more commonly reported as a comorbidity for deaths occurring in hospitals (OR\u2009=\u20091.40, 95%CI: 1.03-1.89) or at home (OR\u2009=\u20091.26, 95%CI: 1.03-1.55), while essential hypertension was more commonly reported with deaths at home (OR\u2009=\u20091.17, 95%CI: 1.01-1.36).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our analysis showed an increase in at-home MND deaths as well as certain comorbidities during the COVID-19 pandemic, suggesting MND patients had a higher likelihood of death from non-COVID-19 comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08258597251349627","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:39Z","timestamp":1750225299000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Place of Death in Patients with Motor Neuron Disease and the Association with Comorbidities During the Coronavirus Disease 2019 Pandemic: A Population-Based Analysis"],"prefix":"10.1177","volume":"41","author":[{"given":"Jaime","family":"Raymond","sequence":"first","affiliation":[{"name":"Agency for Toxic Substances and Disease Registry (ATSDR)\/Centers for Disease Control and Prevention (CDC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Oskarsson","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Larson","sequence":"additional","affiliation":[{"name":"Agency for Toxic Substances and Disease Registry (ATSDR)\/Centers for Disease Control and Prevention (CDC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2832-5917","authenticated-orcid":false,"given":"Suraya","family":"Mohidul","sequence":"additional","affiliation":[{"name":"Hite Consulting Inc., Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Kevin","family":"Horton","sequence":"additional","affiliation":[{"name":"Agency for Toxic Substances and Disease Registry (ATSDR)\/Centers for Disease Control and Prevention (CDC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mehta","sequence":"additional","affiliation":[{"name":"Agency for Toxic Substances and Disease Registry (ATSDR)\/Centers for Disease Control and Prevention (CDC)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000488891"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27450"},{"issue":"5","key":"e_1_3_2_4_2","article-title":"Prognostic factors and epidemiology of amyotrophic lateral sclerosis in Southeastern United States","volume":"8","author":"Engelberg-Cook ESJ","year":"2024","unstructured":"Engelberg-Cook ESJ, Teixeira da Silva Hucke A, Vera-Garcia DV, et al. Prognostic factors and epidemiology of amyotrophic lateral sclerosis in Southeastern United States. Mayo Clin Proc Innov Qual Outcomes. 2024;8(5):482-292.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"e_1_3_2_5_2","unstructured":"www.brooking.edu. COVID-19 and Poverty Vulnerability 2022. https:\/\/www.brookings.edu\/blog\/future-development\/2022\/05\/18\/covid-19-and-poverty-vulnerability\/."},{"key":"e_1_3_2_6_2","unstructured":"COVID-19 to Add as Many as 150 Million Extreme Poor by 2021 The World Bank 2020. https:\/\/www.worldbank.org\/en\/news\/press-release\/2020\/10\/07\/covid-19-to-add-as-many-as-150-million-extreme-poor-by-2021."},{"key":"e_1_3_2_7_2","unstructured":"People with Certain Medical Conditions \u2013 COVID-19 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html."},{"key":"e_1_3_2_8_2","volume-title":"Office of Management and Budget (OMB) Standards","year":"2022","unstructured":"Office of Management and Budget (OMB) Standards. National Institute of Health; 2022. https:\/\/orwh.od.nih.gov\/toolkit\/other-relevant-federal-policies\/OMB-standards."},{"key":"e_1_3_2_9_2","first-page":"1","article-title":"Effects of COVID-19 on motor neuron disease mortality in the United States: A population-based cross-sectional study","volume":"1","author":"Raymond J","year":"2024","unstructured":"Raymond J, Berry JD, Larson T, Horton DK, Mehta P. Effects of COVID-19 on motor neuron disease mortality in the United States: A population-based cross-sectional study. Amyotroph Lateral Scler Frontotemporal Degener. 2024;1-2:1-8.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"e_1_3_2_10_2","volume-title":"US Department of Health and Human Services Regions","year":"2021","unstructured":"US Department of Health and Human Services Regions. US Department of Health and Human Services; 2021. https:\/\/www.hhs.gov\/about\/agencies\/iea\/regional-offices\/index.html."},{"key":"e_1_3_2_11_2","unstructured":"Institute S. SAS 9.4. Cary NC."},{"key":"e_1_3_2_12_2","volume-title":"About the National Vital Statistics System","year":"2016","unstructured":"About the National Vital Statistics System. Centers for Disease Control and Prevention; 2016. https:\/\/www.cdc.gov\/nchs\/nvss\/about_nvss.htm."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004092"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51762"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/bs13100822"},{"key":"e_1_3_2_16_2","unstructured":"Lindquist SB. Maintaining quality care for patients with ALS\u2014Lessons from the pandemic 2022. https:\/\/newsnetwork.mayoclinic.org\/discussion\/maintaining-quality-care-for-patients-with-als-lessons-from-the-pandemic\/."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/003335490512000312"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050361"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1435_20"},{"key":"e_1_3_2_20_2","unstructured":"AJMC. A Timeline of COVID-19 Vaccine Developments in 2021 2021. https:\/\/www.ajmc.com\/view\/a-timeline-of-covid-19-vaccine-developments-in-2021."}],"container-title":["Journal of Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08258597251349627","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08258597251349627","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08258597251349627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:21:39Z","timestamp":1777666899000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08258597251349627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/08258597251349627"],"URL":"https:\/\/doi.org\/10.1177\/08258597251349627","relation":{},"ISSN":["0825-8597","2369-5293"],"issn-type":[{"value":"0825-8597","type":"print"},{"value":"2369-5293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}